1                 Six patients developed human antichimeric antibodies (HACAs) at a level > or =100 ng/

2                   No patient developed human antichimeric antibodies after treatment.

3 r, infusion reactions were common, and human antichimeric antibodies developed in 5 of 14 patients.

4 els, soluble IL-2 receptor levels, and human antichimeric antibody (HACA) activity were evaluated.

5                                        Human antichimeric antibody (HACA) responses were also charact

6                                        Human antichimeric antibody developed in 28% of patients.

7                One patient developed a human antichimeric antibody response predominantly to the muri

8                                        Human antichimeric antibody response was assessed up to 6 mo p

9                                        Human antichimeric antibody response was evaluated with a doub

10 Only one patient made a very low titer human antichimeric antibody response.

11 ediate induction of human antimouse or human antichimeric antibody responses.

12                                        Human antichimeric antibody status did not correlate with surv

13 e of altered pharmacokinetics or serum human antichimeric antibody titers, for a total of no more tha

14                                      A human antichimeric antibody was detected in only one patient.

15 re evaluated 1-6 mo after infusion for human antichimeric antibody, and none developed a response.

16                   No patient developed human antichimeric antibody.

17 ce accurately predicted development of human antichimeric antibody.

18 ) developed an anti-antibody response (human antichimeric antibody/human antimouse antibody).